Synthroid vs Armour Thyroid: A Head-to-Head for Women at Every Life Stage

Import from '@/components/mdx'

What Is the Core Difference Between Synthroid and Armour Thyroid?

Levothyroxine contains only synthetic T4. Your body converts that T4 into the active hormone T3 through a conversion process that varies by person, by stress load, by gut health, and by the genetic variants you carry in the deiodinase enzymes (DIO1, DIO2). Armour Thyroid is porcine-derived and contains both T4 and T3, standardized to a fixed ratio of approximately 38 mcg T4 and 9 mcg T3 per 60 mg (one grain).

That difference is the entire debate in a single sentence. Women who convert T4 to T3 normally often do fine on levothyroxine. Women who carry certain DIO2 polymorphisms may convert poorly and report persistent fatigue, brain fog, or mood changes even when their TSH sits squarely in range.

How Each Drug Works in Your Body

Levothyroxine has a half-life of roughly 6 to 7 days, producing stable serum T4 levels. T3 from Armour Thyroid peaks within 2 to 4 hours of the dose, then drops. That spike is why some clinicians worry about palpitations or anxiety spikes on NDT, particularly in perimenopausal women whose cardiovascular reactivity is already shifting.

The Fixed-Ratio Problem in Armour Thyroid

The physiological T4:T3 ratio in the human thyroid is closer to 20:1. Armour delivers a ratio of about 4:1. Every dose of Armour floods your system with proportionally more T3 than a healthy gland would ever secrete. That excess is manageable in some women and problematic in others, especially those with atrial fibrillation risk or bone density concerns.

How Sex-Specific Physiology Shapes Your Thyroid Medication Choice

Women are 5 to 8 times more likely than men to develop hypothyroidism, which means most of the real-world clinical experience with both drugs lives in female patients. Still, very few randomized trials have been designed with women's hormonal variability in mind. The 2013 Hoang et al. Crossover trial in the Journal of Clinical Endocrinology and Metabolism enrolled 70 patients and found that nearly half (49%) preferred NDT over levothyroxine, with improvements in weight, mood, and cognition. The majority of participants were women. That preference signal is real and should not be dismissed.

Estrogen, Thyroid Binding Globulin, and Your Dose

Estrogen raises thyroid binding globulin (TBG), which ties up more circulating T4 and can push TSH upward. This matters across three distinct windows:

• Oral contraceptive use. Starting combined oral contraceptives may increase your levothyroxine requirement. Monitor TSH 6 weeks after starting or stopping the pill.
• Pregnancy. TBG rises sharply in the first trimester. Levothyroxine dose commonly increases by 25 to 50 mcg within the first 4 to 6 weeks of confirmed pregnancy.
• Perimenopause and menopause. Falling estrogen lowers TBG, which can make previously adequate levothyroxine doses suddenly feel excessive. Free T4 may rise even if TSH stays flat.

Armour Thyroid carries the same TBG sensitivity on its T4 component, but the fixed T3 content adds another layer of variability that makes dose adjustments less precise during hormonal transitions.

Gut Absorption and Female GI Physiology

Levothyroxine absorption is notoriously finicky. It should be taken on an empty stomach, 30 to 60 minutes before food, and separated from calcium, iron, and proton pump inhibitors by at least 4 hours. Women on iron supplementation for heavy periods or pregnancy are at particular risk of under-absorption if they take their levothyroxine and iron together.

Synthroid vs Armour Thyroid Across Reproductive Life Stages

Reproductive Years: Trying to Conceive

Thyroid function directly regulates ovulation. Subclinical hypothyroidism, defined as TSH above 2.5 mIU/L in the TTC window by most fertility specialists, is linked to reduced implantation and early pregnancy loss. The American Thyroid Association's 2017 pregnancy guidelines recommend levothyroxine as the treatment of choice for hypothyroidism in women who are pregnant or planning pregnancy.

Armour Thyroid is not recommended during active fertility treatment. The T3 surge from each dose crosses the placenta more readily than T4, and no adequately powered safety data exists in the TTC population.

Pregnancy and the First Trimester Dose Jump

This section is mandatory reading if you are already on Armour Thyroid and discover you are pregnant.

Levothyroxine dose during pregnancy typically needs to increase by approximately 30% within the first 4 to 6 weeks. Many clinicians advise women on levothyroxine to take two extra doses per week the moment a pregnancy test is positive, then recheck TSH and free T4 within 4 weeks. The target TSH during the first trimester is below 2.5 mIU/L by ATA 2017 pregnancy guidelines.

Armour Thyroid creates dosing uncertainty in pregnancy because the T3 component cannot be titrated independently. If you are on Armour when you conceive, most maternal-fetal medicine specialists and endocrinologists will transition you to levothyroxine immediately. Do not wait for your next scheduled appointment. Call your provider the day you get a positive test.

Levothyroxine is classified as FDA Pregnancy Category A, meaning controlled studies show no fetal risk. Untreated hypothyroidism, by contrast, carries documented risk of miscarriage, preterm birth, and impaired fetal neurodevelopment.

Lactation

Levothyroxine passes into breast milk in very small amounts and is considered safe during breastfeeding. The American Academy of Pediatrics rates it as compatible with lactation. T3 also transfers into breast milk in small quantities. Armour Thyroid has not been studied specifically in lactating women, but given its T3 content, the theoretical exposure to a nursing infant is slightly higher than with levothyroxine alone. The practical difference is likely small, but the data gap is real.

Postpartum Thyroiditis

Postpartum thyroiditis affects 5 to 10% of women in the year after delivery. It typically follows a hyperthyroid phase (1 to 4 months postpartum) followed by a hypothyroid phase (4 to 8 months), with most women recovering to euthyroid status by 12 months. Levothyroxine is the appropriate treatment during the hypothyroid phase if TSH exceeds 10 mIU/L or symptoms are significant. Armour Thyroid is not used here: the T3 content would exacerbate any residual thyrotoxic phase and complicate monitoring.

Perimenopause

This is where the clinical picture gets genuinely nuanced, and where many women first become dissatisfied with levothyroxine monotherapy.

Perimenopause brings fluctuating estrogen and progesterone, sleep disruption, weight gain, brain fog, mood changes, and fatigue. These symptoms overlap almost perfectly with undertreated hypothyroidism. When a woman on a stable levothyroxine dose for years enters perimenopause and suddenly feels worse despite a "normal" TSH, her clinician faces a diagnostic puzzle: is this thyroid, is this sex hormone flux, or is this inadequate T4-to-T3 conversion?

The WomanRx Perimenopause Thyroid Evaluation Framework:

1. Check TSH and free T4, free T3 together, not TSH alone.
2. Assess for DIO2 polymorphism if available (not standard of care, but increasingly accessible through specialty labs).
3. Review whether any menopausal hormone therapy (MHT) has recently started or stopped, since oral estrogen raises TBG and may require a levothyroxine dose increase.
4. If TSH is suppressed or free T3 is elevated, Armour Thyroid is not appropriate.
5. If TSH is mid-range and free T3 sits in the lower third of the reference range despite adequate free T4, a low-dose liothyronine (T3-only) add-on to levothyroxine offers more precise control than switching to Armour.

This framework is the clearest way to map a perimenopausal woman's thyroid picture before making any medication switch.

Post-Menopause and Bone Density

This is where Armour Thyroid carries its most underappreciated risk for women. Excess T3 is a recognized driver of bone resorption. In post-menopausal women who no longer have estrogen's protective effect on bone, even mild over-replacement with T3 can accelerate bone loss. A 2015 systematic review in the Journal of Clinical Endocrinology and Metabolism confirmed that suppressed TSH, regardless of cause, is an independent risk factor for osteoporosis and fragility fracture in older women.

If you are post-menopausal and interested in NDT, your prescriber should check a DEXA scan at baseline and monitor TSH closely to keep it within the normal range, not at the low end.

PCOS, Hashimoto's, and Other Female-Specific Thyroid Contexts

PCOS and Subclinical Hypothyroidism

Up to 27% of women with PCOS have subclinical hypothyroidism, compared with about 4 to 10% of the general population. The thyroid-ovarian axis is bidirectional: TSH receptor expression exists on ovarian tissue, and high TSH may impair follicular development. Whether treatment with levothyroxine improves ovulation and fertility outcomes in women with PCOS and subclinical hypothyroidism remains an open question. No large randomized trial has answered it definitively. Data directly comparing NDT versus levothyroxine in women with PCOS is essentially absent. Levothyroxine is currently preferred given its more predictable dosing in a population already managing insulin resistance and hormonal complexity.

Hashimoto's Thyroiditis

Hashimoto's is the most common cause of hypothyroidism in women of reproductive age. Both levothyroxine and Armour Thyroid treat the hypothyroid consequence of Hashimoto's, but neither drug treats the underlying autoimmune process. A common claim online is that NDT's porcine proteins worsen autoimmunity in Hashimoto's. The evidence for this is thin and largely theoretical. What is documented is that TSH suppression, which is more likely with Armour due to T3 loading, may slightly increase TPO antibody titers in some patients. Keep this in mind if you are monitoring antibody levels.

Head-to-Head Clinical Evidence: What the Trials Actually Show

The Hoang et al. 2013 crossover trial remains the most cited direct comparison. Participants spent 16 weeks on each medication. Those on NDT lost an average of 4 pounds more than those on levothyroxine over the same period. Nearly half preferred NDT. Cognitive scores were slightly better on NDT for some participants. No significant cardiovascular safety differences were detected.

The limitation: 70 participants, mostly female but not stratified by menopausal status, DIO2 genotype, or reproductive intention. Applying these findings universally to a pregnant woman, a 23-year-old trying to conceive, or a 65-year-old with osteopenia overstates the evidence.

The 2014 American Thyroid Association guidelines state that "evidence is insufficient to recommend the routine use of combination T4 plus T3 therapy" but do not prohibit NDT in appropriate non-pregnant patients who have not responded adequately to levothyroxine.

As of early 2025, no head-to-head trial has been powered to study outcomes specifically in perimenopausal or post-menopausal women. This is an explicit evidence gap.

Who Is Armour Thyroid Right For, and Who Should Avoid It?

Likely Appropriate Candidates

• Women with persistent symptoms (fatigue, brain fog, low mood, unexplained weight gain) on stable levothyroxine with TSH in range and free T3 in the lower third of the reference range
• Women who have tried liothyronine add-on and found it impractical or ineffective
• Women who are not pregnant, not actively TTC, and not at elevated fracture risk
• Women who have discussed the evidence gaps openly with a thyroid-literate prescriber and have agreed on a monitoring plan

Women Who Should Not Use Armour Thyroid

• Pregnant women or those actively trying to conceive
• Breastfeeding women where T3 exposure to the infant is a concern
• Women with atrial fibrillation, arrhythmia history, or significant cardiovascular disease
• Post-menopausal women with low bone density or osteoporosis (unless monitoring is meticulous)
• Women with poorly controlled anxiety or palpitations
• Women with a recent Graves' disease history

Switching from Synthroid to Armour Thyroid: What the Process Looks Like

If you and your clinician decide to trial Armour Thyroid, here is the standard approach:

Step 1: Establish baseline labs. TSH, free T4, free T3, and if post-menopausal, a DEXA scan if not recently done.

Step 2: Convert the dose. The approximate conversion is 60 mg (one grain) of Armour Thyroid for every 100 mcg of levothyroxine. Some clinicians start 10 to 20% below the calculated dose to account for the T3 load.

Step 3: Recheck labs at 6 to 8 weeks. Do not rely on TSH alone. Check free T3 and free T4 as well. TSH may be suppressed even when the patient is clinically euthyroid, because exogenous T3 suppresses TSH more than T4 does.

Step 4: Titrate slowly. Armour Thyroid comes in grains (30 mg, 60 mg, 90 mg, 120 mg). Small adjustments take time to stabilize.

Step 5: Know the stopping signals. Persistent palpitations, resting heart rate above 90 bpm, new anxiety, significant sleep disruption, or a falling TSH below 0.4 mIU/L are reasons to reassess.

If switching back to levothyroxine, the reverse conversion applies, and TSH may take 6 to 8 weeks to restabilize.

Pregnancy and Lactation Safety: A Required Clinical Summary

| | Levothyroxine (Synthroid) | Armour Thyroid (NDT) | |---|---|---| | Pregnancy category | FDA Category A | Not formally categorized; NOT recommended | | First trimester dose change | Increase ~30% immediately | Cannot titrate T3 independently; switch to levothyroxine | | Fetal T3 exposure | Minimal (T4 does not readily cross in excess) | Higher (T3 crosses more freely) | | Lactation transfer | Very low; AAP compatible | Small T3 transfer; no formal lactation studies | | Postpartum thyroiditis use | Yes, for hypothyroid phase | Not recommended | | Fertility/TTC window | Preferred; target TSH <2.5 mIU/L | Not recommended |

If you are pregnant or planning pregnancy, levothyroxine is the only evidence-based thyroid replacement option. This is not a close call.

Dosing, Formulations, and Practical Considerations

Levothyroxine is available as branded Synthroid, Levoxyl, Tirosint (a gel capsule with fewer excipients, useful for women with absorption issues or multiple sensitivities), and multiple generics. The FDA has ruled levothyroxine products non-interchangeable without TSH recheck because small formulation differences affect absorption.

Armour Thyroid is manufactured by AbbVie. It has experienced supply shortages that forced patients to switch mid-treatment, disrupting TSH stability. For women in perimenopause or postpartum, where hormonal variability already complicates thyroid management, supply disruptions are a genuine clinical risk.

Generic NDT products (NP Thyroid, Nature-Throid) exist but have varying quality-control histories. Nature-Throid and WP Thyroid both had FDA recalls between 2020 and 2021 for subpotency.